AVSF - Precision Neuroscience 2026, LLC
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$1M
Investors
58
Min Invest
$10,000
What this filing shows
·Every sentence is a value as filed on SEC Form D
AVSF - Precision Neuroscience 2026, LLC is a Delaware limited liability company organized in 2026 that filed a Form D with the SEC on October 13, 2026, describing itself as a venture capital fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(1) and covers equity and pooled investment fund interests. AVSF - Precision Neuroscience 2026, LLC reported $1,035,800 sold from 58 investors in an offering of indefinite size as of the Form D filed October 13, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $10,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 70 Federal Street, 6th Floor, Boston, MA 02110.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Fund Family
Every vehicle in this manager's series as it appears on EDGAR, newest generation first. Sold-to-date and investor counts are each vehicle's latest Form D.
Fund family
AVSF Precision Neuroscience3 vehicles · 0 generations · since 2023 · $4.5M sold across the family
| Vehicle | Role | First filed | Status | Sold | Investors |
|---|---|---|---|---|---|
| Unnumbered · first filed 2023-01-20 · 3 vehicles · $4.5M sold · 323 investors | |||||
| AVSF - Precision Neuroscience 2026, LLCthis issuer | 2026-10-13 | raising | $1.0M | 58 | |
| AVSF - Precision Neuroscience 2022, LLC | 2023-01-20 | closed | $2.3M | 193 | |
| AVSF - Precision Neuroscience 2024, LLC | 2024-10-21 | closed | $1.1M | 72 | |
Grouped from Form D issuer names (generation, sleeve, jurisdiction and legal-form tokens removed); a name-only match, so abbreviated or renamed vehicles can be missed. Sold and investor figures are each vehicle's latest Form D; sleeves that report the same figure share one family-wide total and are counted once. Performance lines are what a public pension plan reports for its own interest in that fund, net, on the plan's cash flows and valuation date; they are not the general partner's figures.
In the Terminal
Filing events
1
latest Oct 13, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
raising
Latest event New filer · Oct 13, 2026
SEC.govInvestor
- 1 filing event with values and deltas, latest 2026-10-13, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Michael Collins
Executive Officer · Manchester, NH
CEO of Alumni Ventures LLC, the Issuer's Sole Manager
Questions About AVSF - Precision Neuroscience 2026, LLC
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is AVSF - Precision Neuroscience 2026, LLC?
AVSF - Precision Neuroscience 2026, LLC is a Delaware limited liability company organized in 2026 that filed a Form D with the SEC on October 13, 2026 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of equity and pooled investment fund interests.
Is AVSF - Precision Neuroscience 2026, LLC legit?
AltStreet does not rate legitimacy; it reports the public record. AVSF - Precision Neuroscience 2026, LLC filed a Form D with the SEC on October 13, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $1,035,800 sold to 58 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is AVSF - Precision Neuroscience 2026, LLC registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that AVSF - Precision Neuroscience 2026, LLC claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has AVSF - Precision Neuroscience 2026, LLC raised?
AVSF - Precision Neuroscience 2026, LLC reported $1,035,800 sold from 58 investors in an offering of indefinite size as of the Form D filed October 13, 2026.
Who can invest in AVSF - Precision Neuroscience 2026, LLC?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $10,000.
What is the minimum investment in AVSF - Precision Neuroscience 2026, LLC?
The Form D lists $10,000 as the minimum investment accepted from any outside investor as of October 13, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling AVSF - Precision Neuroscience 2026, LLC and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind AVSF - Precision Neuroscience 2026, LLC?
The Form D lists 1 related person: Michael Collins, executive officer (CEO of Alumni Ventures LLC, the Issuer's Sole Manager). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is AVSF - Precision Neuroscience 2026, LLC located?
The issuer's address on its SEC filings is 70 Federal Street, 6th Floor, Boston, MA 02110. Its phone number of record is 603-518-8112. It is organized under the laws of Delaware.
How long is the AVSF - Precision Neuroscience 2026, LLC offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is AVSF - Precision Neuroscience 2026, LLC?
The Form D reports a revenue range of $1 - $1,000,000.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.